It is often said that growth hormone promotes bone growth, but this is clearly a misconception, and in 2007, leading experts from major global pediatric endocrine societies in the United States, Europe, and Asia Pacific reached a consensus at a meeting in Mexico that normal doses of growth hormone do not promote bone growth or sexual development. The reason why some people have this opinion is mainly caused by one-sided understanding. Growth hormone is more often used in children with growth hormone deficiency, and in such children, the bone age is often low. After the application of growth hormone to make the growth hormone basically normal, the backward bone age has a tendency to approach the normal bone age, which is easily mistaken as promoting the bone age growth, and there are many children who apply growth hormone and have already entered puberty, and the rapid bone age growth in puberty is also easily mistaken as being caused by growth hormone. Because of the medication period, it is easy to consider any problems that arise toward the effects of the drug. There is enough evidence to show that the use of aromatase inhibitors in boys (because they are not suitable for girls and tend to cause boyishness) prevents the conversion of androgens to estrogens and results in almost no increase in bone age (because they have not been officially approved for the treatment of precocious puberty, they are currently used less clinically and mainly for research), but the amount of aromatase inhibitors does not inhibit the growth of bone age as much as gonadotropin-releasing hormone analogs ( GnRHa), which inhibits growth hormone secretion, and inhibits growth hormone receptor sensitivity. This suggests that the growth of bone age is mainly related to estrogen (which is also present in boys). Besides, growth hormone is often combined with gonadotropin-releasing hormone analogs (GnRHa) to treat true precocious puberty, and if it would significantly promote bone growth, it would not be used for precocious puberty.